Christopher Astle

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Vancouver, British Columbia, Canada
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Daniel Dex, Attorney-in-Fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Christopher Astle

Form 4 holding SVP & Chief Financial Officer

Zymeworks Inc.

Security class
Restricted Stock Unit
Shares / value
30,000
Estimated value
$336,468
Report date
05 Jan 2024
Price
$11.22
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding SVP & Chief Financial Officer

Zymeworks Inc.

Security class
Common Stock
Shares / value
6,503
Estimated value
$72,935
Report date
08 Jan 2024
Price
$11.22
Ownership
Direct
Form 4 holding SVP & Chief Financial Officer

Zymeworks Inc.

Security class
Stock Option (Right to Buy)
Shares / value
125,000
Estimated value
Report date
10 Mar 2022
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding SVP & Chief Financial Officer

Zymeworks Inc.

Security class
Stock Option (Right to Buy)
Shares / value
50,000
Estimated value
Report date
05 Jan 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Christopher Astle

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .